top of page
Image de Olga Guryanova
Image de National Cancer Institute
Image de Lucas Vasques




Get to know Carl Zeiss Medical

The Medical Technology segment of ZEISS offers complete solutions to diagnose and treat ophthalmic diseases. In the field of microsurgery the company provides innovative visualization solutions.


With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, the company supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations. ZEISS also offers visualization solutions for dental treatment and gynecology.


The Gradian ICV is an all-in-one ventilator for intensive and critical care, as well as transport and intermediate care.

  • Versatile Use: With extensive modes and monitoring parameters, in-built turbine, battery backup, and compact form factor, the ICV is easy to use in any location within a hospital, or for transport within or outside the facility.

  • Advanced Ventilation Modes: The ICV is designed to deliver care to infant, pediatric, and adult patients in any setting. It comes standard with a range of invasive and non-invasive ventilation modes to fit the clinical need, as well as optional modes including high flow oxygen therapy.

  • Sophisticated Monitoring: Combining extensive monitoring parameters and respiratory diagnostics with dedicated display pages, the ICV can measure, display, store, and export the information needed for precise, high-quality care.

  • Fully Portable: The ICV’s trolley is designed to easily hold or move the ventilator and accessories, including oxygen cylinder bracket, humidifier, and circuit support arm.

  • Smart CPR Mode: The innovative CPR mode gives step-by-step audible and visual instructions for performing CPR and breathing as per AHA and ERC’s latest guidelines.


We are committed - alongside other stakeholders in the health sector - to reduce, and ultimately do away with, the need for our loved ones to seek “advanced” medical treatments overseas. They deserve to undergo such procedures in a familiar #environment and more importantly surrounded by their family & friends.

To get one step closer to that goal, we are excited to announce our partnership with ZEISS Medical Technology 🇩🇪, an internationally leading #technology enterprise operating in the fields of optics and optoelectronics - Primamed Technologies Ltd is now their exclusive representative in Rwanda 🇷🇼. 


Thanks to this strategic partnership with ZEISS,  we will benefit & learn from their technical know-how of 170+ years, equip & train health professionals in Rwanda & the region 🌍 on the latest ZEISS medical solutions (+ innovations💡). However, we are even more excited by the improvement of the patient experience and the fact that their family will be more confident in the outcome. 


We cannot wait to see the amazing milestones we will reach with ZEISS. We are striving for "greater efficiency, safety, more patients that can be accommodated, and better results".

© Lionel Manzi, External Relations & Partnerships Officer, LinkedIn.

📸: Zeiss.

  • Linkedin

Prof. Dr. Dr. h.c. Frederik Wenz

Chief Medical Officer, CEO of the Medical Center

University of Freiburg


[...] Let’s talk about cancer treatment – what developments do you see in this area that are beneficial to patients?


When it comes to cancer treatment, we will start to see more and more technical devices in use, including robotic assistants for surgery. We will also increase the use of data-driven medicine, which is an area where we can still do a lot. Right now we are basically blind to what happens to the patient before and after the hospital stay, yet there is a lot of data out there on the patient's behavior – including parameters relevant to their condition.


When the patient leaves the hospital, we talk about their outcome measurements. This is where we have to change our approach, especially when it comes to cancer medicine. Sometimes we see a patient on a fixed schedule – every six weeks, or every three months – and we are blind to what happens between these visits. The fact is that some of these patients would need to come more often, and some would need to come less often.


With monitoring devices and sensor systems, we can move from this one-size-fits-all follow-up approach to an adaptive one. Then the patient who needs to see a physician can do so, and patients who don't need treatment do not need to come for an in-person visit.


This is the future of cancer treatment, where digital and other technological developments are used to improve outcomes.

© Zeiss.

  • X
bottom of page